Authors
Jaime Sanz, Allain-Thibeault Ferhat, Anna Maria Raiola, Didier Blaise, Mutlu Arat, Yener Koc, Malek Benakli, Mi Kwon, Alexander Kulagin, Matteo Parma, Simona Sica, Johanna Tischer, Jiri Pavlu, Nathalie Dhedin, Giovanni Grillo, Nicolaus Kröger, Juan Montoro, Sebastian Giebel, Zina Peric, Bipin Savani, Arnon Nagler, Simona Piemontese, Mohamad Mohty, Fabio Ciceri
Published in
Bone marrow transplantation. Nov 25, 2025. Epub Nov 25, 2025.
Abstract
Haploidentical hematopoietic cell transplantation (HCT) is widely used in high-risk acute lymphoblastic leukemia (ALL), yet optimal donor selection remains unclear. We retrospectively analyzed 933 ALL patients receiving post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis to evaluate the impact of donor characteristics on outcomes. Donors had a median age of 36 years; 38% were female, including 23% who donated to male recipients. Peripheral blood (PB) was the graft source in 69%, and CMV-seronegative donors were used in 16% of CMV-negative recipients. Multivariate analysis showed that PB grafts were associated with inferior overall survival (OS) and GVHD-free/relapse-free survival. CMV-matched seronegative pairs had reduced non-relapse mortality and improved OS. Chronic GVHD was more frequent with older donors and in male recipients of female donor grafts, the latter also increasing extensive cGVHD risk. In conclusion, donor and graft selection significantly influence outcomes after haplo-HCT with PTCy. When feasible, bone marrow should be favored over PB grafts, and CMV-seronegative donors prioritized for CMV-seronegative recipients. Older donor age and female-to-male sex mismatch were associated with increased chronic GVHD risk.
PMID:
41291114
Bibliographic data and abstract were imported from PubMed on 26 Nov 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 37
- Comments 0